5 research outputs found

    Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell <i>Mycobacterium tuberculosis</i> Assays

    No full text
    Small-molecule inhibitors of the myco­bacterial transcriptional repressor EthR have previously been shown to act as boosters of the second-line anti­tuberculosis drug ethion­amide. Fragment-based drug discovery approaches have been used in the past to make highly potent EthR inhibitors with ethion­amide boosting activity both <i>in vitro</i> and <i>ex vivo</i>. Herein, we report the development of fragment-sized EthR ligands with nanomolar minimum effective concentration values for boosting the ethion­amide activity in <i>Mycobacterium tuberculosis</i> whole-cell assays

    Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors

    No full text
    Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen <i>Mycobacterium tuberculosis</i> to this antibiotic. We recently reported structure–activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure–property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen <i>Mycobacterium tuberculosis</i>. Thanks to this process, we identified compound <b>42</b> (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration
    corecore